1: Leucht S, Crippa A, Siafis S, Patel MX, Orsini N, Davis JM. Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia. Am J Psychiatry. 2020 Apr 1;177(4):342-353. doi: 10.1176/appi.ajp.2019.19010034. Epub 2019 Dec 16. Erratum in: Am J Psychiatry. 2020 Mar 1;177(3):272. PMID: 31838873.
2: Allen DC, Carlson TL, Xiong Y, Jin J, Grant KA, Cuzon Carlson VC. A Comparative Study of the Pharmacokinetics of Clozapine N-Oxide and Clozapine N-Oxide Hydrochloride Salt in Rhesus Macaques. J Pharmacol Exp Ther. 2019 Feb;368(2):199-207. doi: 10.1124/jpet.118.252031. Epub 2018 Dec 6. PMID: 30523062; PMCID: PMC6337003.
3: Meltzer HY, Share DB, Jayathilake K, Salomon RM, Lee MA. Lurasidone Improves Psychopathology and Cognition in Treatment-Resistant Schizophrenia. J Clin Psychopharmacol. 2020 May/Jun;40(3):240-249. doi: 10.1097/JCP.0000000000001205. PMID: 32332459; PMCID: PMC7188269.
4: Snaith A, Wade D. Dystonia. BMJ Clin Evid. 2014 Feb 28;2014:1211. PMID: 25347760; PMCID: PMC3938056.
5: Arango C, Ng-Mak D, Finn E, Byrne A, Loebel A. Lurasidone compared to other atypical antipsychotic monotherapies for adolescent schizophrenia: a systematic literature review and network meta-analysis. Eur Child Adolesc Psychiatry. 2020 Sep;29(9):1195-1205. doi: 10.1007/s00787-019-01425-2. Epub 2019 Nov 22. PMID: 31758359; PMCID: PMC7497364.
6: Milosavljevic F, Bukvic N, Pavlovic Z, Miljevic C, Pešic V, Molden E, Ingelman-Sundberg M, Leucht S, Jukic MM. Association of CYP2C19 and CYP2D6 Poor and Intermediate Metabolizer Status With Antidepressant and Antipsychotic Exposure: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2020 Nov 25:e203643. doi: 10.1001/jamapsychiatry.2020.3643. Epub ahead of print. PMID: 33237321; PMCID: PMC7702196.
7: Browning JL, Patel T, Brandt PC, Young KA, Holcomb LA, Hicks PB. Clozapine and the mitogen-activated protein kinase signal transduction pathway: implications for antipsychotic actions. Biol Psychiatry. 2005 Mar 15;57(6):617-23. doi: 10.1016/j.biopsych.2004.12.002. PMID: 15780848.
8: Naguy A, Alamiri B, Khraibut B. Weight Loss During Atomoxetine Add-on to Clozapine-Responsive Schizophrenia. Am J Ther. 2018 Nov/Dec;25(6):e774-e775. doi: 10.1097/MJT.0000000000000785. PMID: 29782344.
9: García-Bea A, Miranda-Azpiazu P, Muguruza C, Marmolejo-Martinez-Artesero S, Diez-Alarcia R, Gabilondo AM, Callado LF, Morentin B, González-Maeso J, Meana JJ. Serotonin 5-HT2A receptor expression and functionality in postmortem frontal cortex of subjects with schizophrenia: Selective biased agonism via Gαi1-proteins. Eur Neuropsychopharmacol. 2019 Dec;29(12):1453-1463. doi: 10.1016/j.euroneuro.2019.10.013. Epub 2019 Nov 14. PMID: 31734018.
10: Verdolini N, Hidalgo-Mazzei D, Murru A, Pacchiarotti I, Samalin L, Young AH, Vieta E, Carvalho AF. Mixed states in bipolar and major depressive disorders: systematic review and quality appraisal of guidelines. Acta Psychiatr Scand. 2018 Sep;138(3):196-222. doi: 10.1111/acps.12896. Epub 2018 May 13. PMID: 29756288.